The app gives users the ability to find information on over 1000 animal medicine listings included on the compendium website; with the complete datasheets available for viewing.
The new app also allows you to scan datamatrix barcodes on veterinary medicinal product packaging to take you straight to important product information. You can also search by medication, manufacturer or GTIN.
Dawn Howard, NOAH’s Chief Executive said: "The NOAH Compendium is the recognised industry reference, and it is essential we fully utilise the information offered in the compendium with modern technology, whilst protecting the integrity and respect that it holds.
"The website, which we relaunched earlier this year, has had over 8.5 million views to date. We feel this app serves as a great addition to this modern method of accessing data – meaning users are no longer reliant on internet access to obtain the information they need.
"As an organisation, we will continue to embrace new technologies to ensure animal medicine is used correctly and responsibly in the UK. The launch of this new app goes towards ensuring all those who prescribe or use animal medicines have access to the latest technical information available for companion and farm animals when they need it."
The founders of ioLight, Andrew Monk and Richard Williams, will be in attendance on the Bayer stand to answer questions about the new product.
James Crawford, Head of Marketing at Bayer, said: "Bayer is delighted to present the ioLight microscope on our stand at the London Vet Show 2016. The microscope provides fantastically clear images and is simple to use, showing off Bayer's products for all our customers to see."
Professor Mike Taylor, a Diplomate of the European Veterinary Parasitology College, is in the process of evaluating the ioLight microscope as a tool for the diagnosis of parasitic infections of farm animals.
Normally he uses a laboratory microscope for this work but they are not routinely used on a farm. He has also tried a portable digital microscope, but finds it does not give the resolution required for identification of protozoan parasite species or for counting nematode eggs. Mike said: "The ioLight’s portability, image quality and connectivity to the Apple iPad offer great potential for the development of rapid methods for identifying parasites, or determining parasite burdens. I can envisage its use by both veterinarians and suitably trained livestock farmers, in the practice laboratory or directly on the farm."
Andrew Monk said: "Since our launch earlier this year we have seen a massive interest from the veterinary sector. We are thrilled to have the opportunity to demonstrate our microscope to such a large audience, and are looking forward to working with Bayer."
For more information visit iolight.co.uk or email Andrew Monk at andrew.monk@iolight.co.uk.
The company says Bovela is the only BVD vaccine available proven to provide 12 months’ protection, against both types of BVD, and after only one shot.
Cattle business manager, Robert Bakewell said: "Provided Bovela is used as recommended on the product label, we are happy to guarantee that it will prevent the birth of PI (persistently infected) calves caused by transplacental infection by the BVD virus.
"We are also encouraging farmers to seek advice and input from their vet about BVD control by offering a £50 voucher towards testing for Bovela users. All herd owners need to do is speak to their veterinary surgeon or email bvdzero.uk@boehringer.com."
BVA President Gudrun Ravetz said: "Veterinary View not only highlights some of the veterinary profession's fantastic work, but complements our joint project with RCVS, Vet Futures, in exploring how the profession can best shape its own future. We hope it will stimulate debate among vets, and the wider community in which we work, about both the big challenges and opportunities that the veterinary profession is facing."
The series includes a number of videos which showcase more recent industry developments:
Stem Cell therapy for the treatment of canine osteoarthritis (VetCell Therapeutics)
Pharmtrax, a mobile device for vets to record work and dispensing on the farm (Henry Schein Animal Health)
Hormone implants as an alternative to castration (Virbac Animal Health)
Practice management support from Zoetis
Preventing an epidemic of equine flu (Merial Animal Health)
BVA has added its voice to the Labelling Matters campaign for the introduction of mandatory method of production labelling of meat and dairy products. This would help consumers across the UK to answer the simple questions "How was this animal kept?" and "Did this animal die a humane death?", including stunning before slaughter.
A key element of the Labelling Matters campaign is that mandatory method of production labelling must be underpinned by robust welfare outcome safeguards, with on-farm welfare assessments ensuring that high welfare standards are being achieved.
Legislation for mandatory method of production labelling has been implemented already for shell eggs, which must legally be labelled either as “eggs from caged hens”, “barn eggs”, “free range” or “organic”. Labelling Matters wants to see this principle extended to meat and dairy products from other farmed animals.
The BVA highlights evidence which shows that consumers in the UK and across Europe want clear food labelling with information about animal welfare:
BVA President Sean Wensley said: "For vets it's a top priority that the animals we rear for food have a good life and a humane death. Research shows that vets are not alone in caring about where their food comes from. Mandatory method of production labelling makes sense on a number of fronts: consumers can be clearly and consistently informed about how the animals reared for their meat and dairy products were kept, with on-farm welfare assessments assuring high standards. Mandatory method of production labelling would give unambiguous information to the high numbers of consumers who care about animal welfare when buying meat and dairy products and help ensure market support for British farmers who pride themselves on achieving the highest welfare standards."
Cefshot is indicated for treatment of subclinical mastitis at drying off with action against Gram positive and Gram negative bacteria.
Jude Roberts MRCVS from Zoetis says this makes possible three-way selective dry cow therapy with products from the company's dry cow portfolio: "With evidence-based triage, this covers teat sealant solo, in combination with narrow spectrum cloxacillin, or now with broader spectrum long-acting cephalonium.
"This is in keeping with the trend from milk buyers for increasing precision in the use of antibiotic dry cow therapy, and only when it is justified in the first place."
Dry periods longer that 54 days require milk withhold for 96 hours. For shorter dry periods, milk withhold is 58 days. Meat withhold period is 21 days.
Cefshot is available in multiples of 24 and 120 tubes, for delivery September onwards.
SRD remains a significant problem for the swine industry1. Associated production losses include 30-70% morbidity, a mortality rate of 4-6% (and even higher in severely affected units), decreased feed efficiency and reduced growth rates2.
Zactran contains gamithromycin. Merial says this bactericidal azalide rapidly accumulates in target lung tissue in less than 30 minutes, where it reaches and exceeds the MBC* for SRD pathogens for an extended period, helping to relieve clinical signs and minimise lung damage.
Zactran has a dose rate of 1ml per 25kg in pigs, administered by intramuscular injection.
The product is available in three pack sizes: 50ml glass bottle and 100ml and 250ml polypropylene shock-resistant bottles, and has a 3 year shelf-life.
References
*MBC: Minimum Bactericidal Concentrations. MBC is the lowest concentration of drug which reduces bacterial counts by 99.9% (CVMP/627/01)
Each week, the email will cover a different topic concerning either dairy, beef, sheep, pigs, poultry or gamebirds. The information, which is personalised with the practice details, can then be forwarded to clients who have an interest in that particular area, for example a resource on mastitis could be sent to dairy farmers and their staff.
Mike Howe, Veterinary Director at NADIS said: "We are confident that practices will recognise the value of the NADIS material and utilise this free service, as it will not only help to raise disease awareness, but will also assist vets in encouraging farmers to think about optimising their herd health. All NADIS materials promote veterinary health planning as the most effective way of preventing disease, and promote the vet’s role on the farm."
The resources also offer an opportunity for farmers and their staff to gain a City & Guilds unit of accreditation. A module can be completed by passing all the quizzes from each disease resource, providing an easy and flexible way for farmers and farm employees to gain recognised qualifications.
For more information, visit: www.nadis.org.uk.
Metacam 40 mg/ml solution for injection for cattle and horses contains 40 mg/ml of meloxicam, and is available in either 50 ml or 100 ml presentations. It is approved for subcutaneous or intravenous use in cattle, and intravenous use in horses.
Boehringer says the introduction comes on the back of a recent large-scale landmark study that found adding Metacam to standard antibiotic therapy for mastitis resulted in a greater first-service conception rate, fewer inseminations required to conceive and a higher probability of pregnancy by 120 days post-calving when compared to cows receiving antibiotic therapy alone1.
Boehringer Ingelheim’s technical manager Kath Aplin said: "By reducing the pain and inflammation caused by mastitis and other conditions, the use of Metacam 40 can result in improvements in cattle health and welfare, and may help limit any reduction in feed intakes. This is central to efficient herd management and productivity."
The company adds that new Metacam 40 mg/ml formulation offers a lower volume dose compared to the existing 20 mg/ml presentation, giving vets more flexibility in their use of Metacam.
James Hutchings, Head of Sales for Bimeda UK, said: "The launch of Tetroxy Vet highlights our ongoing commitment to providing UK veterinarians with a choice of high quality veterinary pharmaceuticals at a fair price."
Bimeda says the benefits of Tetroxy Vet include:
Tetroxy Vet is available in a 100ml pack size.
Velactis (cabergoline) is a POM marketed by Ceva Animal Health, used in the herd management programme of dairy cows as an aid in abrupt drying-off, by reducing milk production.
The product was authorised through the European Medicines Agency (EMA) in December 2015 and was first sold in the UK in April 2016.
The VMD says it has been made aware of reports of serious adverse events, predominantly occurring in Denmark, involving recumbency (lying down and unable to rise) and some deaths. Most adverse events occurred within 8 to 24 hours following product administration. Anecdotal evidence suggests that hypocalcaemia treatments may be successful in reversing clinical signs.
Ceva has decided to stop further distribution of the product in Europe voluntarily, pending the outcome of further investigations to assess a possible causal link between the product and the adverse events reported.
The VMD, EMA, other agencies throughout Europe and the MAH are working closely to monitor the situation.
The VMD highlights that due to the nature and use of the product there is no risk to human health or consumer safety.
Vets and dairy farmers are strongly encouraged to report any adverse events associated with use of Velactis to the VMD using its online reporting form or directly to Ceva for further investigation by the MAH as necessary.
At the start of June, the British Veterinary Association (BVA), British Cattle Veterinary Association (BCVA), Goat Veterinary Society (GVS), and Sheep Veterinary Society (SVS) welcomed the announcement that bluetongue (BTV-8) vaccine would be available by mid-July to support farmers and smallholders in managing the risk of a bluetongue outbreak predicted to reach mainland UK by late summer.
Since the Defra risk assessment indicates a high risk by late summer of a BTV incursion from France, veterinary associations have been involved in discussions with government, farmers’ representatives and manufacturers to ensure vaccine is available to meet potential demand particularly in the south of England where risk is highest. The situation remains under constant review by Defra as the disease develops and the weather warms up, promoting midge activity.
Pharmaceutical companies MSD and Zoetis announced that batches of vaccine would be available from mid-July, which Defra has just confirmed.
Vets across the UK are also contributing to the Joint campaign Against Bluetongue (JAB), helping to make farmers aware of the risk, clinical signs and what action to take, through speaking at local JAB information events and displaying posters and leaflets in practices.
While welcoming the announcement of vaccine availability in June, veterinary organisations also sought clarification about the cost and the amount of vaccine likely to be available in July and thereafter. This information is now available.
BVA President Sean Wensley said: "We welcome the announcement that vaccine will be available in time to meet potential demand. This disease seriously affects animal health and welfare as well as the productivity of livestock, and vaccination is the key control."
Photo by Fourrure (http://www.boulesdefourrure.fr) [CC BY-SA 2.0], via Wikimedia Commons
The new 10ml (10-dose) and 100ml (100-dose) packs of Ingelvac PRRS EU are available now, and will complement the existing 50ml (50-dose) packs.
Callum Blair MRCVS, Swine Brand Manager at Boehringer Ingelheim, said: "Nobody likes to end up with part used bottles of any vaccine that then have to be discarded. The addition of Ingelvac PRRS EU 10-dose and 100-dose packs will provide choice for different sized units and help reduce wasted doses."
For more information, visit www.prrs.com.
During the 60 days before to 30 days after calving, dairy cows experience a dip in their natural immunity, leaving them especially vulnerable to important diseases such as mastitis2, metritis3 and retained placenta.4 With serious cost consequences and implications for cow welfare and productivity, this makes the transition period one of the most challenging yet vital periods for vets to manage with dairy clients.
Imrestor (pegbovigrastim injection) is a pegylated form of the naturally occurring protein cytokine, bovine Granulocyte Colony Stimulating Factor (bG-CSF). Elanco says it helps restore the cow’s natural defences by increasing the number and restoring the function of neutrophils, the primary type of white blood cell that recognizes and kills harmful bacteria.
Fiona Anderson, Technical Vet at Elanco, said: "It’s no secret that a successful transition period is vital for maximising productivity in the next lactation, yet we are still ‘firefighting’ common transition diseases like mastitis rather than focusing on their true cause."
"Vets are under increasing pressure to adopt a more proactive approach, not least to reduce the use of antibiotics in livestock but with few credible alternatives. This can be challenging in dairy herds, particularly around calving when cows are susceptible to multiple disease challenges while their defences are low. Imrestor helps to restore a cow’s own natural immunity and strengthen her ability to defend against infection by a range of mastitis pathogens – thus helping to protect the cow against mastitis when she needs it most."
Available in pre-filled, single-dose syringes, Imrestor is administered with two injections – one seven days prior to the anticipated date of calving and the other within 24 hours after calving – with neither injection requiring a withdrawal period.
Kingsley Baxendale, Ruminant Marketing Manager at Elanco Animal Health said: "It can be extremely frustrating for vets to see their dairy farmers struggling with the stress and hassle of dealing with increased numbers of sick cows during calving; they have enough to deal with at the moment. We’re delighted that Imrestor can provide vets with a tool to help decrease the negative consequences associated with immune-related diseases like mastitis and maximise their herds’ lactation potential."
As part of the launch of Imrestor, Elanco also announced its new 'Pledge To Protect' initiative to encourage vets and farmers to make a pledge symbolising their commitment to address immune suppression in their dairy cows.
The number of pledges will be tracked using a life-sized 2D cow model, pictured above. For each pledge, which can be made online or at events, Elanco will make a £5 donation to The Royal Agricultural Benevolent Institution (R.A.B.I), which supports farmers in difficulty. As a thank you for showing support, all pledgers will automatically be entered into a weekly prize draw.
To find out more about using Imrestor and how you can make your pledge, visit www.vital90days.co.uk.
Bovalto Respi vaccines contain a newly developed combination of viral and bacterial antigens. Merial says the recent vaccine isolates effectively target current European-circulating Bovine Respiratory Disease (BRD) strains. Bovalto antigens are also proven by challenge, including at six months post-vaccination to confirm long-lasting protection.
Henry Berger, Global Head of the Ruminant and Equine Business Unit at Merial, said: "Merial is committed to understanding the needs of cattle producers and delivering unique, targeted solutions. Merial is dedicated to expanding its portfolio of parasiticides, vaccines and other disease prevention solutions, with high-value products like Bovalto Respi, to improve productivity, and keep herds healthy."
Merial highlights that BRD is complex to manage and each year affects an estimated 1.9 million animals1, costing the UK cattle industry around £60 million2. In Ireland BRD is responsible for 30% of deaths in stock under one-year old3.
At a Merial symposium at WBC 2016, Prof. Sandro Cavirani, Director of the Department of Animal Health at the University of Parma, Italy highlighted the importance of successful BRD control programmes in calves to optimise herd immunity and productivity, including early, repeated and targeted BRD vaccination.
Bovalto Respi 3 contains strains of Parainfluenza Virus 3, Bovine Respiratory Syncytial Virus, and Mannheimia haemolytica serotype A1. The combination in Bovalto Respi 4 combines the three pathogens in Bovalto Respi 3, with the added strain of Bovine Viral Diarrhoea Virus (BVDV).
According to statistics from the RCVS, almost 40% of veterinary surgeons that have registered in the UK since 2005 qualified from veterinary schools elsewhere in the EU.
Of course, it's not just in general practice that veterinary surgeons and veterinary nurses from other EU member states make such an important contribution. They work across all areas of veterinary science, including the fields of animal health and welfare, animal disease surveillance, scientific research and education, wildlife conservation, and public health and food safety.
Figures from the Veterinary Public Health Association (VPHA) estimate that over 90% of vets in meat hygiene services are non-British EU citizens.
To highlight the impact of Brexit on the veterinary profession, the BVA has written to the Secretary of State, Liz Truss MP, and to Ministers in Scotland, Wales and Northern Ireland, requesting an early statement to the effect that non-British EU vets and vet nurses who are currently living, studying or working in the UK will continue to be able to do so in future.
BVA is also seeking reassurance for UK veterinary professionals working and studying in other EU member states.
BVA President Sean Wensley said: "It is not yet possible to comment on the reality of ‘Brexit’ since much will depend on forthcoming negotiations and the decisions that will be taken by the Government regarding, for example, whether or not to maintain existing EU legislation and rules. However, we recognise that these unanswered questions are having a profound impact on many of our members – particularly members who are non-British EU citizens, or have family members who are, and members who work alongside colleagues from other European Member States."
In the letters, Mr Wensley wrote: "I am sure there are many significant issues that your Department needs to consider [and] given the profound personal impact that the uncertainty caused by the referendum outcome is having on some of our members, we wanted to contact you at the earliest opportunity. In the forthcoming negotiations about the future relationship between the UK and the EU, we strongly urge you to make the case for all EU citizens and EU-qualified veterinary surgeons and nurses to have ongoing rights to live, work and study in the UK."
In the letter to the Northern Ireland (NI) Minister of Agriculture, Environment and Rural Affairs Michelle McIlveen MLA, the BVA President and BVA NI Branch President Seamus O’Kane highlighted NI’s land border with EU member state the Republic of Ireland and called for the maintenance of the Common Travel Area to facilitate movement in an all-island context for both work and study purposes.
VPHA President Lewis Grant said: "Due to the particular focus on public health in many European veterinary degree courses, EU vets make an enormous contribution to both public health and animal health and welfare in the UK - often behind closed doors, monitoring and protecting public health in Approved Premises as well as welfare at slaughter to ensure slaughterhouses meet the standards that are required by law and expected by the public. Without their input and expertise, it would be difficult to ensure that Statutory requirements within the food industry are complied with."
Described as a first-of-its-kind, mobile-enabled digital whitepaper, the publication offers veterinary surgeons and farmers a resource on ketosis, scientific insights on the impact of the disease, and tools to help optimize dairy herd management.
According to the company, the whitepaper reveals that ketone bodies play a more significant role in metabolic diseases than was previously realized, and that beta-hydroxybutyrate is a good indicator of the presence of subclinical ketosis in dairy cattle.
Rinse Boersma, Dairy Species Manager, Animal Health, Bayer said: "Recognizing the significance of ketone bodies is a positive step towards further enhancing dairy cattle health and welfare. Veterinarians can now reliably detect the presence of subclinical ketosis in dairy herds with a simple blood test, and act quickly with the appropriate corrective measures to arrest disease progression."
Also at Congress, Bayer revealed its enhanced BCS Cowdition smartphone application, designed to support ease and accuracy of body condition scoring (BCS) of dairy cows. Bayer says the upgrade helps farmers to improve herd health management by enabling assessment of individual cows’ BCS scores based on its lactation cycle, alerts for cows that need to be attended to, and a dashboard that offers farmers an overview of their entire herd’s health.
BCS Cowdition is available in 10 languages and is free for download from the AppStore and GooglePlay.
Having been told at school that he'd never cut it as a veterinary surgeon, Julian qualified from Liverpool in 1981. He became a partner at Banovallum Vets in Horncastle in 1989 and later the sole owner. Along the way, he also gained AP status in Sheep and Animal Welfare and served as President of the Sheep Veterinary Society and the Lincolnshire Veterinary Association. Oh, and in 1991, he was part of a team that set a world record relay time cycling from Land's End to John O'Groats, raising £8,500 in the process.
Then, in 2012, everything changed. Julian had a cycling accident during a road race in Lincolnshire. He fractured his skull and suffered multiple brain haemorrhages, broken ribs, a fractured shoulder and a punctured lung. Doctors told his wife he'd be unlikely to survive.
But survive he did, and with his injuries precluding a return to practice, he's reinvented himself as an author and approved para-cyclist.
His book is a collection of light-hearted anecdotes and memories from his life in practice, with practical advice about what to try and avoid when working as a veterinary surgeon.
And yes, he was once called out to attend a cow stuck in a tree!
You can buy the book on Amazon in hardcover for £12.95, here: http://www.amazon.co.uk/Julian-Earl/e/B01EVCT67K/ref=sr_ntt_srch_lnk_1?qid=1461874827&sr=1-1
Zoetis has announced that a batch of the bluetongue vaccines, Zulvac® 8 Bovis and Zulvac® 8 Ovis, is expected to become available to veterinary practices in mid-July, in time to manage the risk of an outbreak predicted by Defra to reach mainland UK by the late summer.
The company says the quantity of vaccine will not be unlimited and that it will strive to achieve as widespread availability as possible.
The two vaccines (Bovis for cattle and Ovis for sheep) are licensed to “prevent viraemia” caused by bluetongue virus serotype 8 (BTV-8). Prevention of viraemia, the presence of bluetongue virus in the blood, ensures no onward spread of infection via the blood sucking Culicoides midge.
The vaccines can be used in cattle from three months of age, or six weeks in sheep, requiring two doses three weeks apart in either species. Each dose is 2ml administered intramuscularly in cattle or subcutaneously in sheep, and onset of immunity is 25 days after the second dose. The vaccine provides immunity for a full 12 months.
The British Veterinary Association (BVA), British Cattle Veterinary Association (BCVA), Goat Veterinary Society (GVS), and Sheep Veterinary Society (SVS) welcomed the announcement from Zoetis, and another from MSD, but sought clarification about the cost and the amount of vaccine likely to be available in July and thereafter.
BVA President Sean Wensley said: "We welcome the announcement that vaccine will be available in time to meet potential demand. This disease seriously affects animal health and welfare as well as the productivity of livestock, and vaccination is the key control. While it is good news that vaccine will be available, we know that both farmers and vets will have questions about cost and whether there will a limit to the amount of vaccine available in July. It would be helpful to have these questions clarified as soon as possible."
Located in the South East of England, the centre is part of the new School of Veterinary Medicine at the University of Surrey, and one of the UK's largest veterinary pathology centres, offering high-containment post-mortem examination facilities and histopathology.
The centre is staffed by a team of board-certified veterinary pathologists, veterinary investigation officers and technicians, with expertise in farm-animal, equine, exotic and small-animal pathology.
The new building centres on a large containment level 2 post-mortem examination room with high ceilings, natural lighting, post-mortem examination tables, biological safety cabinets and integrated cold rooms, all served by a powerful winch system which means that post-mortem examinations can be performed on a wide range of species. A viewing gallery overlooks the suite and post-mortem examinations can be recorded and streamed for training purposes.
Professor Roberto La Ragione, Director of the Veterinary Pathology Centre, said: "Veterinary pathology is a growing discipline and its importance has been highlighted in recent disease outbreaks and the important role veterinary pathologists make in drug development. Helping the farming community to be more effective, sustainable and innovative, the Centre will work with partners, businesses and researchers to address some of the unique challenges faced by the veterinary and scientific community.
"It is the close relationships with our external clinical and scientific partners that enables us to be innovative in our approach to education and training here at the Surrey. An example of the latter is the use of digital pathology in teaching, research and diagnostics, which was the subject of discussion at the recent launch of the Veterinary Health Innovation Engine (vHive).
"Together with our partners such as the National Physical Laboratory and the 5G Innovation centre, the Centre is at the forefront of the digitalisation of pathology and innovative big data management.
"The Centre offers the opportunity to inspire the next generation of veterinary pathologists and complements the centres of excellence that already exist in other vet schools and research institutes."
Elanco is highlighting new research which shows that using monensin in dairy cows at high risk of developing subclinical ketosis reduces curative antibiotic use by 25%.
According to the company, good herd management before calving is known to mitigate antimicrobial use in cows suffering from subclinical ketosis related conditions, but to date little research has quantified it.
The new research, by the University of Toulouse, was presented to leading cattle vets, academics and representatives of the pharmaceutical industry by veterinary cattle health specialist, Professor Didier Raboisson at the European Buiatrics Forum in Rome in October.1 It showed that using a monensin bolus in cows at high risk of getting subclinical ketosis led to a 25% reduction in antibiotics to treat and cure conditions associated with the metabolic condition.
Fiona Anderson MRCVS of Elanco said: "Responsible use of antimicrobials must be the target for veterinary medicine. Reducing use by whatever means could help improve the antimicrobial resistance situation. This new study shows that using monensin, which is available in the form of a Kexxtone bolus, is a powerful way to cut antibiotic use in the dairy herd. This is in addition to monensin already proven to be a valuable tool to reduce the risk of ketosis and subclinical ketosis and its associated losses in dairy herd productivity and profitability."
Subclinical ketosis is very common. It can affect up to 30% of cows in early lactation with a large variation between herds.2 It can be very costly for a dairy herd. A study from 2015 found that for a 100 cow herd with 30% ketosis, the direct and indirect costs can be around £10,416 or around £347 per affected cow.3
Cows affected by subclinical ketosis are at a higher risk of getting mastitis and metritis. They are also at higher risk of developing displaced abomasum, retained placenta and cystic ovaries and consequently face a higher culling risk. Subclinical ketosis also lowers milk production, reduces conception rates and lengthens calving intervals.4
If ketosis is an issue in a dairy herd, targeted administration of monensin in a Kexxtone bolus to cows at high risk of developing ketosis reduces the incidences of ketosis by 74%.6
The bolus is given three weeks before calving and provides coverage during the main risk period for the condition. Kexxtone uses monensin to improve rumen function and increase glucose delivery. This ultimately increases the energy available and buffers the dairy cow against the tendency to drop into negative energy balance.5
To make a big difference to clients’ profitability, Fiona encourages vets to not just consider the traditional nutritional intervention and the emergency treatment of ketosis cases, but to develop an effective strategy to highlight cows at risk of subclinical ketosis and to take targeted preventative action. She said: "Vets who can offer positive interventions to subclinical ketosis and its associated losses in the dairy herd are going to be increasingly important to their clients’ herd health planning."
References:
The ioLight microscope fits in a jacket pocket and the company says it is both simple to use and robust. It unfolds to record and share 5MP still images and real time HD video at a magnification of x200 on an iPad Air. The resolution is 1 micron or 1/1,000 mm, powerful enough to see the structure of plant and animal cells.
The microscope uses standard microscope slides and has adjustable top and bottom illumination for use on both biological and opaque samples.
Iolight says it is particularly good for live samples which deteriorate on the journey back to the lab, and it works anywhere, even without a WiFi or mobile phone network.
Andrew Monk, who founded ioLight with business partner Richard Williams, said: "It takes just a couple of minutes to get a great image on the microscope, anywhere from a river bank to a factory floor. This makes microscopy simpler for everyone, from experienced professionals to student scientists."
The ioLight microscope can be ordered now from www.iolight.co.uk, priced at £840 including VAT.
According to the company, 88% of farmers say blowfly is the most widespread ectoparasite affecting sheep in the UK1 and 94% of sheep farmers have been caught out by the parasite in the past2.
The Met Office believes this winter may have been the warmest ever recorded, prompting fears that these favourable conditions will result in a more abundant blowfly population this year.
Fiona Anderson, Technical Consultant Manager at Elanco Animal Health, said: "It’s crucial we do not get complacent when it comes to blowfly – the costs of inaction can be devastating. It’s an extremely distressing disease to see in sheep, and obviously for the sheep themselves, so there’s no sense in taking the risk. Farmers should take control of the situation, before blowfly strikes their flock, by using preventative products with full fleece protection. Another benefit of using a preventative product early in the season is that killing flies from the first wave of the insects reduces the total number of flies for the rest of the season.
"Waiting for clear signs of the blowfly season before acting is a gamble. Farmers are extremely busy and blowfly strike can establish very quickly, so it would be very easy to miss an affected sheep."
Fiona added: "IGRs, such as CLiK and CLiKZiN, stop blowfly larvae developing into the harmful second and third stages that cause flystrike and stock damage. Using an IGR directly off shears saves time by avoiding the need to re-gather sheep and offering a longer period of protection."
For more information on blowfly strike and prevention with IGRs, visit www.farmanimalhealth.co.uk
Hysolv Animal Health has announced the launch of Salmovac 440, a new live salmonella vaccine for poultry which the company claims gives earlier, stronger and longer-lasting immunity than other salmonella vaccines.
The vaccine is given orally through the water supply in a three-dose regime that protects against Salmonella Enteritidis (SE) and Salmonella Typhimurium (ST). It also protects against other SE strains and the newly-emerging monophasic Salmonella Typhimurium strains.
Hysolv says the advantage for farmers is that the vaccine strain is robust and can survive in more hostile conditions. It therefore remains effective where the water delivery system is less than ideal.
The first dose is administered from Day 1 followed by a second dose at six weeks and a third as early as 11 weeks. Salmovac 440 protects chicks after six days and remains effective for up to 63 weeks after the third vaccination, providing an extra four weeks of protection.
Hysolv says another important benefit to egg producers is that the earlier final vaccination at 11 weeks means that the birds can be moved into the laying house as early as 16 weeks old if required — a significant management advantage on some farms.
During the development of the vaccine it was found that the third live vaccination tended to ‘shut down’ any prolonged shedding of the vaccine strain. This, coupled with the earlier vaccination at 11 weeks, helps solve the issue of the vaccine strain being found at transfer to the layer house. Dr Daniel Windhorst, salmonella vaccine specialist with IDT Biologika, said: "If any should be found, the new PCR (Polymerase Chain Reaction) test shrinks the testing time to just two to three hours."
Daniel added: "Although the UK has one of the lowest percentages of salmonella in its flocks, almost one-third of cases were of S Typhimurium. In most continental countries the percentage is much higher, so the extra cover provided by this vaccine is important."
Salmovac 440 has been approved for use by the British Egg Industry Council, which administers the Lion Code.
Merial has announced the launch of Nexus (http://merialnexus.co.uk), a new online information resource which offers large animal vets and Suitably Qualified Persons (SQPs) CPD training modules, webinars, technical articles, product information, marketing tools and support materials.
Victoria Hudson, Marketing Manager for Merial’s Large Animal Portfolio said: "We know that it can be difficult for busy vets and SQPs to find the time to attend CPD sessions in the evenings. Our new Nexus online portal gives access to resources and training modules that can help vets and SQPs stay up-to-date with the latest thinking, best practice, and enhance their knowledge in the field of large animal health at a time that suits them.
"Merial is committed to providing high quality Continuing Professional Development (CPD); bringing the knowledge, expertise and experience which backs up our well-known brands online, to help support professional development."
The Nexus portal includes a range of online courses and modules aimed at SQPS in particular, participation in which can earn AMTRA points. The company says it will be adding further CPD throughout the year, including AMTRA accredited courses.
Merial is offering the chance to win £200 in Amazon vouchers to eligible individuals who register at merialnexus.co.uk from now until the 22nd April 2016.